Cervomed Inc CRVO

$1.37 -0.06 (-4.20%)

Valuation

Market cap
21,620,000
Revenue TTM
$4,010,000
Net income TTM
$-26,970,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-672.57%
Debt to equity
0.00

Trading

Volume
195,500
Avg volume
276,600
Day's range
$1.29 – $1.43
Shares out
15,119,000
Stochastic %K
11%
Beta
-0.62
Analysts
Strong Buy
Price target
$18.00

Price

Company profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease...

Show more

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 744 4400
Website
https://www.cervomed.com
Address
20 Park Plaza, Suite 424, Boston, United States

Latest news

Stocktwits

StellaLunaSun Nov 11, 9:23 AM
$CRVO wrong, they downgraded the stock price to 6 dollar
0 replies
walker7782 Nov 11, 12:36 AM
$CRVO Still watching! Trading near its 52-week low (~$1.37–$1.42) following Q3 results, tight balance sheet ($19.6M cash) and the need for a partner to fund Phase 3 DLB. Sentiment is wonky given the financing overhang, but selling appears exhausted heading into near-term binary events, CTAD biomarker readout next week (Nov 16–19) and Phase 2a stroke data by year-end. Speculative setup waiting on a partner catalyst and I’m getting close to hopping back in briefly.
0 replies
Adorno99 Nov 10, 8:59 PM
$CRVO no--Roth maintained its price target at $7 . Hang on to your shares. The bashers are out in force!
1 replies
Stu_padasso Nov 10, 5:03 PM
$CRVO what is the bullshit case now? i mean bullish its done
1 replies
Marcos125 Nov 10, 4:45 PM
$CRVO CervoMed price target lowered to $6 from $7 at Roth Capital 🙂🙂
1 replies
Tariqlati Nov 10, 11:51 AM
$CRVO toward r/s ?
0 replies
5layer Nov 9, 5:27 PM
$CRVO .
0 replies
Adorno99 Nov 9, 1:45 PM
$CRVO beat expectations revenue and share price. Shorts still holding it down for now.
2 replies